PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2022.0042023551304-313Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Seong Kyu Park, Jee Hyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun, Jong-Ho Wonhttp://e-crt.org/upload/pdf/crt-2022-004.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2022.004, http://e-crt.org/upload/pdf/crt-2022-004.pdf
Transplantation and Cellular Therapy10.1016/s2666-6367(22)00683-22022283S408-S409Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) As Conditioning Therapy for Autologous Transplantation in Patients with Relapsed or High Risk Non-Hodgkin Lymphoma: A Multicenter Randomized Phase II Study By the Consortium for Improving Survival of Lymphoma (CISL)Jong-Ho Won, Kyoung Ha Kim, Seug Yun Yoon, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Sung Kyu Park, JeeHyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Munhttps://api.elsevier.com/content/article/PII:S2666636722006832?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2666636722006832?httpAccept=text/plain
Clinical Lymphoma Myeloma and Leukemia10.1016/s2152-2650(22)00544-4202222S153P-214: Busulfan plus cyclophosphamide and etoposide versus high-dose melphalan as conditioning in autologous stem cell transplantation for newly diagnosed multiple myelomaSungnam Lim, Seon Yang Park, Yongjun Leehttps://api.elsevier.com/content/article/PII:S2152265022005444?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2152265022005444?httpAccept=text/plain
Transplantation and Cellular Therapy10.1016/s2666-6367(23)00292-02023292S174Busulfan Plus Cyclophosphamide and Etoposide Versus High-Dose Melphalan As Conditioning in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple MyelomaSung-Nam Limhttps://api.elsevier.com/content/article/PII:S2666636723002920?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2666636723002920?httpAccept=text/plain
Modern Chemotherapy10.4236/mc.2013.240072013020457-65Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphomaNeelima Vidula, Andrew M. Evens, Irene B. Helenowski, Borko Jovanovic, Jane N. Winter, Jayesh Mehta, Seema Singhal, Stephanie F. Williams, Olga Frankfurt, Jessica K. Altman, Joanne Monreal, Leo I. Gordonhttp://www.scirp.org/journal/PaperDownload.aspx?DOI=10.4236/mc.2013.24007, http://www.scirp.org/journal/doi.aspx?DOI=10.4236/mc.2013.24007, http://www.scirp.org/journal/doi.aspx?DOI=10.4236/mc.2013.24007
Biology of Blood and Marrow Transplantation10.1016/j.bbmt.2011.12.1272012182S246Busulfan, Cyclophosphamide, Etoposide (BUCYVP) or Carmustine, Etoposide, Cytarabine, Melphelan (BEAM) for Conditioning Prior to Autologous Stem Cell Transplantation (ASCT) in Patients with Hodgkin Lymphoma (HL)?G. Salem, A.S. Ruppert, Y. Efebera, P. Elder, A. Bingman, S. Penza, L.A. Andritsos, S.M. Devinehttps://api.elsevier.com/content/article/PII:S1083879111006872?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1083879111006872?httpAccept=text/plain
Annals of Hematology10.1007/s00277-020-03942-62020994819-828Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphomaDo Young Kim, Joo-seop Chung, Jae-Cheol Jo, Su-Hee Cho, Ho-Jin Shinhttp://link.springer.com/content/pdf/10.1007/s00277-020-03942-6.pdf, http://link.springer.com/article/10.1007/s00277-020-03942-6/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00277-020-03942-6.pdf
Transplant International10.1111/tri.13664202033101211-1219Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with non‐Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphomaKyoung Ha Kim, Won Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Cheolwon Suh, Hye Jin Kang, Chul Won Choi, Ho Sup Lee, Sung Hwa Bae, Jinny Park, Eun Kyung Park, Jae‐Yong Kwak, Mark Hong Lee, Byung Woog Kang, Sung‐Kyu Park, Jong‐Ho Wonhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Ftri.13664, https://onlinelibrary.wiley.com/doi/pdf/10.1111/tri.13664, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/tri.13664, https://onlinelibrary.wiley.com/doi/pdf/10.1111/tri.13664
Clinical Lymphoma Myeloma and Leukemia10.1016/j.clml.2018.02.0082018184272-279Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in LymphomaSigal Grisariu, Michael Y. Shapira, Reuven Or, Batia Avnihttps://api.elsevier.com/content/article/PII:S2152265017318499?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2152265017318499?httpAccept=text/plain
Acta Haematologica10.1159/00004656920011054222-232Cytoreduction and Stem Cell Mobilization with a Regimen of Paclitaxel, Etoposide and Cyclophosphamide Followed by Autologous Transplantation Using a Preparative Regimen of Busulfan, Etoposide and Cyclophosphamide for Patients with Advanced LymphomaP.J. Tutschka, S.A. Bilgrami, J.M. Feingold, R.L. Edwards, R.D. Bona, B. Naqvi, J. Clivehttps://www.karger.com/Article/Pdf/46569, https://www.karger.com/Article/Pdf/46569